Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment ...
Symptomatic cerebral cavernous malformation is a rare disease, and affected individuals are at risk of strokes due to intracerebral haemorrhage or new non-haemorrhagic neurological deficits.
10h
Clinical Trials Arena on MSNNovartis reports Phase III efficacy and safety outcomes of SMA treatmentIn this trial, the efficacy and safety of the therapy were evaluated against a sham control in treatment-naïve SMA Type 2 ...
In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...
Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...
Current FDA approval of this adaptive system is for the treatment of Parkinson’s only, not essential tremor, dystonia (a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results